BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

635 related articles for article (PubMed ID: 15325132)

  • 1. Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer's Tg2576 mice.
    LaRue B; Hogg E; Sagare A; Jovanovic S; Maness L; Maurer C; Deane R; Zlokovic BV
    J Neurosci Methods; 2004 Sep; 138(1-2):233-42. PubMed ID: 15325132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease.
    Poduslo JF; Curran GL; Wengenack TM; Malester B; Duff K
    Neurobiol Dis; 2001 Aug; 8(4):555-67. PubMed ID: 11493021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation.
    Kandimalla KK; Curran GL; Holasek SS; Gilles EJ; Wengenack TM; Poduslo JF
    J Pharmacol Exp Ther; 2005 Jun; 313(3):1370-8. PubMed ID: 15743932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons.
    Clifford PM; Zarrabi S; Siu G; Kinsler KJ; Kosciuk MC; Venkataraman V; D'Andrea MR; Dinsmore S; Nagele RG
    Brain Res; 2007 Apr; 1142():223-36. PubMed ID: 17306234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood-brain barrier permeability correlates with medial temporal lobe atrophy but not with amyloid-beta protein transport across the blood-brain barrier in Alzheimer's disease.
    Matsumoto Y; Yanase D; Noguchi-Shinohara M; Ono K; Yoshita M; Yamada M
    Dement Geriatr Cogn Disord; 2007; 23(4):241-5. PubMed ID: 17310121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor-mediated transport of human amyloid beta-protein 1-40 and 1-42 at the blood-brain barrier.
    Poduslo JF; Curran GL; Sanyal B; Selkoe DJ
    Neurobiol Dis; 1999 Jun; 6(3):190-9. PubMed ID: 10408808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain.
    Deane R; Du Yan S; Submamaryan RK; LaRue B; Jovanovic S; Hogg E; Welch D; Manness L; Lin C; Yu J; Zhu H; Ghiso J; Frangione B; Stern A; Schmidt AM; Armstrong DL; Arnold B; Liliensiek B; Nawroth P; Hofman F; Kindy M; Stern D; Zlokovic B
    Nat Med; 2003 Jul; 9(7):907-13. PubMed ID: 12808450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice.
    Kandimalla KK; Wengenack TM; Curran GL; Gilles EJ; Poduslo JF
    J Pharmacol Exp Ther; 2007 Aug; 322(2):541-9. PubMed ID: 17505020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms.
    Deane R; Wu Z; Sagare A; Davis J; Du Yan S; Hamm K; Xu F; Parisi M; LaRue B; Hu HW; Spijkers P; Guo H; Song X; Lenting PJ; Van Nostrand WE; Zlokovic BV
    Neuron; 2004 Aug; 43(3):333-44. PubMed ID: 15294142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiological and biophysical factors that influence Alzheimer's disease amyloid plaque targeting of native and putrescine modified human amyloid beta40.
    Kandimalla KK; Curran GL; Holasek SS; Gilles EJ; Wengenack TM; Ramirez-Alvarado M; Poduslo JF
    J Pharmacol Exp Ther; 2006 Jul; 318(1):17-25. PubMed ID: 16565169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model.
    Ujiie M; Dickstein DL; Carlow DA; Jefferies WA
    Microcirculation; 2003 Dec; 10(6):463-70. PubMed ID: 14745459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of dietary fatty acids on the cerebral distribution of plasma-derived apo B lipoproteins with amyloid-beta.
    Takechi R; Galloway S; Pallebage-Gamarallage MM; Wellington CL; Johnsen RD; Dhaliwal SS; Mamo JC
    Br J Nutr; 2010 Mar; 103(5):652-62. PubMed ID: 19860996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Permeability and residual plasma volume of human, Dutch variant, and rat amyloid beta-protein 1-40 at the blood-brain barrier.
    Poduslo JF; Curran GL; Haggard JJ; Biere AL; Selkoe DJ
    Neurobiol Dis; 1997; 4(1):27-34. PubMed ID: 9258909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood-brain barrier transport of circulating Alzheimer's amyloid beta.
    Zlokovic BV; Ghiso J; Mackic JB; McComb JG; Weiss MH; Frangione B
    Biochem Biophys Res Commun; 1993 Dec; 197(3):1034-40. PubMed ID: 8280117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease.
    Donahue JE; Johanson CE
    J Neuropathol Exp Neurol; 2008 Apr; 67(4):261-70. PubMed ID: 18379441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma.
    Poduslo JF; Curran GL; Kumar A; Frangione B; Soto C
    J Neurobiol; 1999 Jun; 39(3):371-82. PubMed ID: 10363910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of LRP1 [correction of LPR1] at the blood-brain barrier in streptozotocin-induced diabetic mice.
    Hong H; Liu LP; Liao JM; Wang TS; Ye FY; Wu J; Wang YY; Wang Y; Li YQ; Long Y; Xia YZ
    Neuropharmacology; 2009; 56(6-7):1054-9. PubMed ID: 19285094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain to blood efflux transport of adenosine: blood-brain barrier studies in the rat.
    Isakovic AJ; Abbott NJ; Redzic ZB
    J Neurochem; 2004 Jul; 90(2):272-86. PubMed ID: 15228584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.
    Imbimbo BP; Del Giudice E; Colavito D; D'Arrigo A; Dalle Carbonare M; Villetti G; Facchinetti F; Volta R; Pietrini V; Baroc MF; Serneels L; De Strooper B; Leon A
    J Pharmacol Exp Ther; 2007 Dec; 323(3):822-30. PubMed ID: 17895400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta.
    Adlard PA; Cherny RA; Finkelstein DI; Gautier E; Robb E; Cortes M; Volitakis I; Liu X; Smith JP; Perez K; Laughton K; Li QX; Charman SA; Nicolazzo JA; Wilkins S; Deleva K; Lynch T; Kok G; Ritchie CW; Tanzi RE; Cappai R; Masters CL; Barnham KJ; Bush AI
    Neuron; 2008 Jul; 59(1):43-55. PubMed ID: 18614028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.